The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ADI-PEG 20 and FOLFOX6: A phase 1 study in pts (pts) with advanced hepatocellular carcinoma (HCC).
 
James J. Harding
Consulting or Advisory Role - Bristol-Myers Squibb; CytomX Therapeutics; Lilly
Research Funding - Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Incyte (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Polaris (Inst); Polaris (Inst)
 
Richard K. G. Do
No Relationships to Disclose
 
Ellen Hollywood
No Relationships to Disclose
 
Khrystyna Uhlitskykh
No Relationships to Disclose
 
Emily Valentino
No Relationships to Disclose
 
Peter Justin Wan
No Relationships to Disclose
 
Casey R. Hamilton
No Relationships to Disclose
 
Jessica Frick
Employment - Polaris
Stock and Other Ownership Interests - Polaris
Travel, Accommodations, Expenses - Polaris Consulting
 
Xiaoxing Feng
Employment - Polaris
Stock and Other Ownership Interests - Polaris
Travel, Accommodations, Expenses - Polaris
 
Amanda Johnston
Employment - Polaris
Stock and Other Ownership Interests - Polaris
Travel, Accommodations, Expenses - Polaris
 
John S. Bomalaski
Employment - Polaris
Leadership - Polaris
Stock and Other Ownership Interests - Polaris
Patents, Royalties, Other Intellectual Property - Patents
Travel, Accommodations, Expenses - Polaris
 
Chien-Feng Li
No Relationships to Disclose
 
Eileen Mary O'Reilly
Consulting or Advisory Role - Agios (I); Amgen; Antengene (I); Aptus Clinical; ASLAN Pharmaceuticals (I); Astellas Pharma (I); AstraZeneca (I); Bayer (I); Boston Scientific (I); Bristol-Myers Squibb; Bristol-Myers Squibb (I); CASI Pharmaceuticals (I); CASI Pharmaceuticals (I); Celgene; Celsion (I); CytomX Therapeutics; Daiichi Sankyo (I); Debiopharm Group (I); Delcath Systems (I); Eisai (I); Exelixis (I); Gilead Sciences; Halozyme (I); Inovio Pharmaceuticals; Ipsen (I); Merck (I); Merrimack; Onxeo (I); PCI Biotech (I); Sanofi; Sanofi; Servier (I); Silenseed; Sillajen (I); Sirtex Medical (I); Yakult Pharmaceutical (I)
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Incyte (Inst); Mabvax (Inst); Momenta Pharmaceuticals (Inst); OncoMed (Inst); Roche (Inst)
 
Ghassan K. Abou-Alfa
Consulting or Advisory Role - Agios; Amgen; Antengene; Aptus Clinical; ASLAN Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb (I); CARsgen Therapeutics; CASI Pharmaceuticals; Celgene; Celgene (I); Celsion; CytomX Therapeutics (I); Daiichi Sankyo; Debiopharm Group; Delcath Systems; Eisai; EMD Serono (I); Exelixis; Gilead Sciences (I); Halozyme; Halozyme (I); Inovio Pharmaceuticals; Ipsen; Medimmune; Merck Serono; Onxeo; PCI Biotech; Roche; Sanofi (I); SERVIER; Silenseed (I); Sillajen; Sirtex Medical; Sirtex Medical; Vicus Therapeutics (I); Yakult Pharmaceutical
Research Funding - Agios (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); CASI Pharmaceuticals (Inst); Celgene (Inst); Exelixis (Inst); Genentech (Inst); Incyte (Inst); Lilly (Inst); MabVax (Inst); MedImmune (Inst); Momenta Pharmaceuticals (Inst); Novartis (Inst); OncoMed (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Polaris